Amicus Therapeutics to Present Extensive Research on Fabry and Pompe Diseases at WORLDSymposium 2025
• Amicus Therapeutics will showcase 16 presentations at WORLDSymposium 2025, featuring comprehensive research on migalastat for Fabry disease and cipaglucosidase alfa plus miglustat for Pompe disease.
• Key studies include long-term patient outcomes from the FollowME Fabry Pathfinders registry and real-world evidence of treatment effectiveness in both rare diseases.
• Notable research highlights treatment satisfaction, quality of life improvements, and clinical outcomes in patients switching from existing therapies to Amicus' novel treatment approaches.
European Commission Approves GSK's Jemperli Plus Chemotherapy for Advanced Endometrial Cancer
• The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy for first-line treatment of advanced or recurrent endometrial cancer.
• The approval expands the indication to include patients with mismatch repair proficient/microsatellite stable (MMRp/MSS) tumors, representing approximately 75% of cases.
• The RUBY trial demonstrated a 31% reduction in the risk of death with Jemperli plus chemotherapy compared to chemotherapy alone, with a median OS of 44.6 months.
• Jemperli, a PD-1 blocking antibody, is now an approved immuno-oncology-based treatment option for all patients with advanced endometrial cancer in the EU.
Lerociclib Plus Fulvestrant Shows Promise in HR+/HER2- Advanced Breast Cancer
• The LEONARDA-1 phase 3 trial demonstrated that lerociclib plus fulvestrant significantly improved progression-free survival (PFS) compared to placebo plus fulvestrant in patients with HR+/HER2- advanced breast cancer.
• The combination of lerociclib and fulvestrant showed a manageable safety profile, with hematological toxicities being the most common adverse events, effectively managed with dose adjustments.
• Lerociclib plus fulvestrant exhibited efficacy across various patient subgroups, including those with primary endocrine therapy resistance and liver metastasis, addressing a critical unmet need.
• The study supports lerociclib plus fulvestrant as a potential treatment option for patients with HR+/HER2- advanced breast cancer who have progressed on prior endocrine therapy.
Novel uPAR-Targeting Imaging Agent FG001 Shows Promise in Oral and Oropharyngeal Cancer Surgery
A phase II clinical trial demonstrates the efficacy of FG001, a novel uPAR-targeting near-infrared imaging agent, in the intraoperative detection of oral and oropharyngeal squamous cell carcinoma, achieving 100% sensitivity in tumor detection.
LEVI-04 Demonstrates Significant Pain and Function Improvement in Knee Osteoarthritis
• LEVI-04, a novel neurotrophin-3 inhibitor, significantly improved pain and function in patients with knee osteoarthritis (OA) compared to placebo in a phase 2 trial.
• The study demonstrated statistical significance in primary and secondary endpoints at weeks 5 and 17, with over half of LEVI-04 treated patients experiencing at least a 50% pain reduction.
• LEVI-04 was well-tolerated, showing no increased incidence of serious adverse events or joint pathologies, including rapidly progressive OA, compared to placebo.
• The findings suggest LEVI-04's potential in treating OA pain and possibly other pain indications, warranting further investigation into its structure-modifying capabilities.
Semaglutide Shows Promise in Reducing Knee Osteoarthritis Pain in Landmark Trial
• A recent study reveals that semaglutide, the active ingredient in Ozempic, significantly reduces knee pain in patients with osteoarthritis.
• Participants in the trial experienced nearly a 50% reduction in knee pain, a scope of improvement previously unseen with other drugs.
• The study suggests semaglutide's anti-inflammatory effects, in addition to weight loss, contribute to the observed pain reduction.
• Researchers express concern about the potential return of arthritis pain upon discontinuation of semaglutide treatment and subsequent weight regain.
Semaglutide Shows Promise in Easing Knee Arthritis Pain in Obese Patients
• Semaglutide, the active agent in Ozempic and Wegovy, led to a significant weight loss of nearly 14% in obese patients after 68 weeks, compared to 3% in the placebo group.
• The weight loss from semaglutide resulted in a notable decrease in knee pain and improved knee function among patients with obesity-related knee osteoarthritis.
• Study participants taking semaglutide experienced a 42-point reduction in knee pain on a 100-point scale, versus a 28-point reduction in the placebo group.
• Semaglutide could offer a less expensive alternative to knee replacement surgery for obese individuals suffering from worsening knee arthritis.
Antidepressant Escitalopram Shows Potential to Enhance Memory and Cognitive Function
• A new study indicates that the antidepressant escitalopram (Lexapro) may improve memory and cognitive skills in patients.
• The research links escitalopram's cognitive benefits to increased activity in the brain's 5HT4 serotonin receptor.
• Cognitive tests showed improved recall ability in patients treated with escitalopram for eight weeks, correlating with enhanced 5HT4 receptor function.
• Future research will explore drugs specifically targeting the 5HT4 receptor to treat cognitive impairments, regardless of depression symptoms.
© Copyright 2025. All Rights Reserved by MedPath